Greetings from ST Pharm’s CEO, Moo Je Sung! Mooje Sung was appointed as the new CEO of ST PHARM. Having worked at Novartis for 20 years, Dr. Sung is one of the co-developers of the FDA-approved breast cancer treatment Kisqali. We look forward to our bright future of innovative medicine and drug development with Dr. Sung at the forefront. Please show him your warmest greetings and stay tuned with our updates to see how our organization continues to grow and flourish under CEO Sung’s valuable expertise. #STPharm #Innovation #Science #CDMO
소개
“ST Pharm provides reliable and timely custom manufacturing services for API following stringent quality system and close communication with the clients.” Founded in 1983, ST Pharm (formerly known as Samchully Pharmaceutical) has been offering excellent custom manufacturing services of APIs and their intermediates to meet clients’ high expectation for their use in pharmaceutical development in compliant to cGMP requirements. Our reliability in service, which is well-proven through decades of business relationship with many big pharmas and biotech clients, is the essence of our strength along with our expertise in process development and scale-up optimization. Historically, ST Pharm has been focusing our expertise on nucleoside based active pharmaceuticals in various antiviral drug applications; we became the world largest supplier of Thymidine in the late 1990s and Zidovudine in the mid 2000s and protected nucleosides in the early 2000s. ST Pharm has continuously been expanding its service offering, including synthesis of therapeutic oligonucleotides. In June 2010, ST Pharm became a subsidiary of Dong-A Pharmaceutical, the top pharmaceutical company in Korea. ST Pharm is committed to expanding its business scope into generic APIs and their intermediates with full support and collaboration with parent company Dong-A Pharmaceutical.
- 웹사이트
-
https://www.stpharm.co.kr/en
에스티팜 외부 링크
- 업계
- 제약
- 회사 규모
- 직원 501 - 1,000명
- 본사
- Seoul
- 유형
- 상장기업
- 설립
- 1983
- 전문 분야
- New Drug APIs & Intermediates (Anti HCV/HIV/AIDS), Generic APIs & Intermediates (Anti-Viral Cancer Coagulant hypertensive), Oligonucleotides & Amidites & Nucleoside Monomers (Anti-Cancer) 및 mRNA CDMO (5'-cap, LNP)
위치
에스티팜 직원
업데이트
-
🌟 Join us at #CPHIMilan! Visit us at #Booth24D31 in the Integrated Pharma Zone to discuss the future of pharma! Explore cutting-edge insights from ST Pharm’s RNA experts on service offerings, technical capabilities, RNA market trends, next-generation technology, RNA therapeutics, and more. 🌟 Special Events: ◾ Free Gelato 🍦 : daily from 15:00 to 17:00 ◾ Raffle Draws🎁 : October 8-9 at 16:00 / October 10 at 14:00 Don’t miss out on these exciting opportunities, including chances to win Samsung Electronics products! 😉 Looking forward to seeing you there! #STPHARM #Innovation #mRNA #RNA #CDMO #SouthKoreaCDMO
-
-
에스티팜님이 퍼감
I am happy to attend OTS meeting in Montreal! We will present the poster and booth. ST Pharm folks are ready to support your programs for monomers, oligos, and mRNA. I am looking forward to meeting you all. Thanks.
-
-
🚀 Exciting news! ST PHARM will be attending the 20th Annual Meeting of the Oligonucleotide Therapeutics Society from October 6 to 9 in Montreal, Canada. Join us at Booth 3-16, where we will be sharing our latest advancements in manufacturing and analysis for oligonucleotides and mRNA. We can't wait to see you there! #Oligonucleotides #mRNA #STPharm #OTS2024 #Montreal
-
-
Did you enjoy the networking event at ChemOutsourcing 2024? 에스티팜 had a successful day and met new friends from the global pharma industry. Our speech topic was “How Our Long Journey of Nucleoside Chemistry Meets CRISPR Cas,” and we were able to present ST Pharm and our RNA technology platform to the audience. During the speech, our principal manager from the Business Department, HJ (Hyuk-jun) Jung, shared his insights on RNA markets and related market forecasts, as well as ST Pharm’s technology history. Please remember that ST Pharm’s CDMO service, based on its extensive knowledge and technical platform leading to RNA, will streamline your processes in the most optimized way. #STPharm #SmallMolecule #CDMO #ChemOutsourcing #SouthKorea #TechnologyDriven #RNACDMO #NucleosideChemistry
-
-
🚀 Are you heading to #CPHIMilan ? ST PHARM is excited to participate in the 35th CPHI Worldwide in Milan from October 8th to 10th! Join us at #Booth24D31 in the Integrated Pharma Zone, where we’ll be showcasing our latest innovations and connecting with over 2,400 exhibitors and 62,000 attendees from 166+ countries. Let’s discuss the future of pharma! Explore cutting-edge insights from ST Pharm’s RNA experts on service offerings, technical capabilities, RNA market trends, next-generation technology, #RNA therapeutics, and more. For any inquiries, please contact : info@stpharm.co.kr Looking forward to seeing you there! #CPHIMilan #Innovation #mRNA #STPharm #CDMO #SouthKoreaCDMO
이 콘텐츠는 여기에서 사용할 수 없습니다.
LinkedIn 앱에서 이 콘텐츠 등 이용하기
-
🥇 에스티팜 Awarded EcoVadis 'Gold' Medal 🥇 We are thrilled to announce that ST Pharm’s Banwol Campus has been awarded the 'Gold' medal by EcoVadis! This achievement follows our receipt of the 'Bronze' medal in 2019, marking a significant milestone in our sustainability journey. EcoVadis is a leading global sustainability rating agency that evaluates companies based on Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. Receiving the Gold medal reflects our ongoing commitment and excellence in these critical areas. CEO Moo Je Sung stated, “As a leading global CDMO company, we actively respond to stakeholder demands and transparently share our sustainability efforts. This approach is essential for maintaining our competitive edge. We will continue to uphold our vision as an innovative company dedicated to social responsibility and ethical management.” This milestone underscores ST Pharm’s dedication to sustainable practices and corporate responsibility. We look forward to advancing towards a brighter and more sustainable future. #STPharm #Sustainability #EcoVadis #GoldMedal #CorporateResponsibility #Innovation
-
🌟 Exciting News from ST Pharm! 🌟 We are thrilled to announce that 에스티팜 will be showcasing a groundbreaking poster session on Basroparib (STP1002), a first-in-class tankyrase inhibitor (TNKSi), at the ESMO Congress 2024! We warmly invite you to visit our poster and delve into the results of the Phase 1 clinical trial of Basroparib (STP1002). This is an excellent opportunity to engage with our research and discuss potential advancements in cancer treatment. 🔗 View Presentation Details Posters - ESMO Congress 2024 (ctimeetingtech.com) For any questions or further information, please don’t hesitate to reach out to us at stp.nddi@stpharm.co.kr We look forward to seeing you at ESMO 2024! #ESMO2024 #STPharm #Basroparib #STP1002 #CancerResearch #ClinicalTrials #Innovation
-
-
Join ST PHARM at ChemOutsourcing 2024 from September 3rd to 6th! We're excited to showcase the latest pharmaceutical innovation at Parsippany Hilton Hotel in New Jersey. Visit Booth 2 to learn how ST Pharm streamlines small molecule process through R&D experts and CMC integrated offerings. Don’t miss our Principle Manager HJ (Hyuk Jun) Jung's presentation on Thursday, Sept. 5, at 2:00 PM, where he'll share exclusive insights in Nucleoside Chemistry to xRNA. We look forward to seeing you there! #STPharm #ChemOutsourcing #Innovation #CDMO #APIManufacturing #smallmolecule #oligonucleotide #xRNA
-
-
🚀 ST PHARM is on the Move! 🚀 We’re excited to share our Q4 schedule with all of our followers. Join us at these key industry events: 🔬 Chem Outsourcing 🔬 OTS Meeting 🔬 CHPI Milan 🔬 Tides Europe Meet our executives, dive into our latest research, and experience our innovative developments firsthand. Detailed information for each event will be shared soon! Stay tuned and connect with us as we continue to drive progress in the pharmaceutical industry. #CDMO #STPharm #DrugDevelopment #Innovation #Pharmaceutical
-